000			01743nam a22001937a 4500
008			210810b1999 ||||| |||| 00| 0 eng d
020			_a9780190941925
082			_a615.19 PAR-A
100			_aParrill, Abby L.
245			_aRational drug design : _bnovel methodology and practical applications / _cAbby L. Parrill and M. Rami Reddy
260			_aLas Vegas _bAmerican Chemical Society _c1999
300			_a374 p.
365			_aINR _b2995.00.
500			_aOverview of Rational Drug Design, Conformational and Energetic Aspects of Receptor-Ligand Recognition, New Free Energy Calculation Methods for Structure-Based Drug Design and Prediction of Protein Stability, Binding Evaluation Using the Finite Difference Solution to the Linearized Poisson-Boltzmann Equation and salvation Entropy Correction, SmoG: A Ligand Design Method Based on Knowledge-Based Parametrization of a Solvent Reorganization Model, The Evaluation of Multi-Body Dynamics for Studying Ligand-Protein Interactions: Using MBO (N)D to Probe the Unbinding Pathways of Cbz-Val-Phe-Phe-Val-Cbz from the Active Site of HIV-1 Phase, Calculation of Relative Hydration Free Energy Differences for Heteroaromatic Compounds: Use in the Design of AMP Deaminase Inhibitors, New Tools for Rational Drug Design, Rational Approaches to Inhibition of Human Osteoclast Cathepsin K and Treatment of Osteoporosis, Building a Hypothesis for Nucleotide Transport Inhibitors Unified Pharmacophoric Model for Cannabinoids and Aminoalkylindoles Derived from Molecular Superimposition of CB Cannabinoid Receptor Agonists CP55244 and WIN55212-2.
650			_aCombinatorial chemistry
650			_aDrugs--Design
650			_aDrugs--Structure-activity relationships
700			_aReddy, M. Rami
999			_c67088 _d67088